Hos patienter, som udvikler tegn på alvorlige reaktioner, især alvorlig dyspnø, bronchospasme eller hypoxi, skal infusionen straks afbrydes.
Patients who develop evidence of severe reactions, especially severe dyspnoea, bronchospasm or hypoxia should have the infusion interrupted immediately.